VolitionRx: Advancing the science of epigenetics

Published on: May 24, 2022
Author: Editor

VolitionRx is a leading diagnostic company dedicated to advancing the science of epigenetics through their patented platform: Nucleosomics™. Recently, Volition signed a large license and supply agreement with Heska worth $28M. VolitionRx also announced the financial results of 2022 Q1 and Business Update on May 11, 2022.

Scott Powell, the VP of Investor Relations of VolitionRx, joined our CEO Interview program a year ago and spoke at our GCFF events a few times. This time, we are excited to hear about the recent progress of the company. Volition has defined business into four distinct pillars. Which one of them has the most potential? What are the major milestones in 2022? How did Volition’s recent launch in Singapore on Nu.Q Vet come along? And lastly, what catalyst should investors expect in the next 12 months? Check them out at today’s CEO Interview!

About VolitionRx Limited (NYSE AMERICAN: VNRX)

Volition is a multi-national epigenetics company that applies its Nucleosomics™ platform through its subsidiaries to develop simple, easy to use, cost effective blood tests to help diagnose and monitor a range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. Early diagnosis and monitoring have the potential to not only prolong the life of patients, but also to improve their quality of life. The tests are based on the science of Nucleosomics™, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid – an indication that disease is present. Volition is primarily focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.

Volition’s research and development activities are centered in Belgium, with an innovation laboratory in California and additional offices in Texas, London, and Singapore, as the company focuses on bringing its diagnostic and disease monitoring products to market.

For more information, please visit the website.

NAI500’s new CEO Interview series is a program where we invite CEOs and senior executives of exciting public companies to uncover great investment opportunities for every day investors. If you don’t want to miss out on the great opportunities that we bring, subscribe to our YouTube channel and other social media channels below!

Disclaimer: NAI is being compensated for this content. Materials contained in this content are for information purposes only and is not intended to constitute an offering of securities in any jurisdiction. Nothing on this content should be construed as an offer, solicitation or recommendation to buy or sell products or securities.

Life Science Technology